Artivion (NYSE:AORT) Releases Quarterly Earnings Results, Beats Estimates By $0.03 EPS

Artivion (NYSE:AORT) released its earnings results on Thursday. The company reported $0.17 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.14 by $0.03, FiscalAI reports. The business had revenue of $118.30 million for the quarter, compared to analyst estimates of $116.42 million. Artivion had a positive return on equity of 5.98% and a negative net margin of 2.16%.

Artivion Stock Performance

Shares of AORT traded up $0.61 during midday trading on Thursday, reaching $40.71. 776,175 shares of the stock were exchanged, compared to its average volume of 319,709. The stock’s 50 day simple moving average is $43.86 and its 200 day simple moving average is $42.77. The company has a market cap of $1.93 billion, a P/E ratio of -169.63 and a beta of 1.59. Artivion has a twelve month low of $21.97 and a twelve month high of $48.25. The company has a quick ratio of 2.88, a current ratio of 3.93 and a debt-to-equity ratio of 0.50.

Insider Buying and Selling at Artivion

In other news, SVP Jean F. Holloway sold 7,315 shares of Artivion stock in a transaction that occurred on Wednesday, December 3rd. The shares were sold at an average price of $45.30, for a total value of $331,369.50. Following the completion of the sale, the senior vice president directly owned 156,093 shares in the company, valued at approximately $7,071,012.90. The trade was a 4.48% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Marshall S. Stanton sold 47,376 shares of the business’s stock in a transaction that occurred on Friday, November 21st. The shares were sold at an average price of $45.04, for a total value of $2,133,815.04. Following the completion of the sale, the senior vice president owned 44,753 shares of the company’s stock, valued at approximately $2,015,675.12. This trade represents a 51.42% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 141,234 shares of company stock valued at $6,366,621 in the last quarter. Company insiders own 7.60% of the company’s stock.

Hedge Funds Weigh In On Artivion

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Royal Bank of Canada lifted its position in shares of Artivion by 107.0% during the 1st quarter. Royal Bank of Canada now owns 38,707 shares of the company’s stock valued at $952,000 after acquiring an additional 20,010 shares during the period. AQR Capital Management LLC raised its stake in Artivion by 8.8% in the first quarter. AQR Capital Management LLC now owns 35,053 shares of the company’s stock valued at $862,000 after purchasing an additional 2,823 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in Artivion by 4.6% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 23,591 shares of the company’s stock worth $580,000 after purchasing an additional 1,032 shares during the period. Creative Planning grew its stake in Artivion by 5.6% during the second quarter. Creative Planning now owns 14,272 shares of the company’s stock worth $444,000 after buying an additional 753 shares in the last quarter. Finally, Invesco Ltd. increased its holdings in Artivion by 40.8% in the 2nd quarter. Invesco Ltd. now owns 481,026 shares of the company’s stock valued at $14,960,000 after buying an additional 139,370 shares during the period. 86.37% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on AORT shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Artivion in a report on Wednesday, January 21st. Oppenheimer restated an “outperform” rating and set a $50.00 price objective on shares of Artivion in a research note on Friday, November 7th. Canaccord Genuity Group reiterated a “buy” rating and issued a $51.00 target price on shares of Artivion in a research note on Wednesday, December 17th. Citizens Jmp lifted their price target on Artivion from $47.00 to $53.00 and gave the stock a “market outperform” rating in a report on Friday, November 7th. Finally, Wall Street Zen downgraded Artivion from a “strong-buy” rating to a “buy” rating in a research note on Saturday, January 24th. Seven research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Artivion has a consensus rating of “Moderate Buy” and a consensus target price of $49.11.

About Artivion

Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.